Novo shares rise as US Medicare price cuts come in largely as expected

Core Insights - Novo Nordisk shares increased by 5% following analysts' reports that U.S. price cuts for semaglutide were largely in line with expectations [1] Company Summary - The price adjustments for semaglutide, a key product of Novo Nordisk, were anticipated by analysts, leading to a positive market reaction reflected in the share price increase [1]